Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease asso europapress.es - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europapress.es Daily Mail and Mail on Sunday newspapers.
ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development
Jon Kratochvil joins as Vice President for Business Development Licensing for North America
ERS Genomics Limited ( ERS ), which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced the appointment of Jon Kratochvil as Vice-President for Business Development Licensing for North America.
With over 30 years of experience, Jon becomes a core member of ERS global team. Jon joins ERS from MilliporeSigma where he was Director of Business Development and Licensing, with responsibility for all global development opportunities for the company s gene editing and novel modalities technologies. In his role as Business Development Director for Washington University Jon was pivotal in generating over $70 million in revenue from a portfolio of over 1,000 life science technologies. Prior to this he was a licensing mana
Share this article
Share this article
ResearchAndMarkets.com s offering.
Targeting the CD47-SIRPa axis is emerging as one of the most promising new cancer immunotherapy approaches seeking to target innate immune response. This report reveals intense global interest and a growing list of stakeholders operating in this field. Users of this report get an un-biased, fact driven analysis of the position of each molecule and commercial player, always kept up to date with twice weekly updates.
This analytical tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of immune-oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your drug surveillance and intelligence of the CD47-SIRPA axis in oncology, allowing you to power your decision making and advance your own interests.
Search jobs 10-Dec-2020 CollPlant to Supply rhCollagen to STEMCELL Technologies for Use in a Broad Range of Cell Culture Applications REHOVOT, Israel and VANCOUVER, BC, Dec. 10, 2020 /PRNewswire/ CollPlant (NASDAQ: CLGN), a regenerative medicine company, and STEMCELL Technologies, Canada s largest privately owned biotechnology company, which develops cell culture media, cell separation systems, instruments, and other reagents for life sciences research, today jointly announced they have entered into a product manufacturing and supply agreement. CollPlant will sell its proprietary recombinant human Type I collagen (rhCollagen), the world s first plant-based rhCollagen, to STEMCELL Technologies, which will incorporate CollPlant s product into cell culture media kits.
CollPlant to Supply rhCollagen to STEMCELL Technologies for Use in a Broad Range of Cell Culture Applications
USA - English
News provided by
Share this article
Share this article
REHOVOT, Israel and VANCOUVER, BC, Dec. 10, 2020 /PRNewswire/ CollPlant (NASDAQ: CLGN), a regenerative medicine company, and STEMCELL Technologies, Canada s largest privately owned biotechnology company, which develops cell culture media, cell separation systems, instruments, and other reagents for life sciences research, today jointly announced they have entered into a product manufacturing and supply agreement. CollPlant will sell its proprietary recombinant human Type I collagen (rhCollagen), the world s first plant-based rhCollagen, to STEMCELL Technologies, which will incorporate CollPlant s product into cell culture media kits.